Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (9330)
All Articles published online
|
Publishing Process of This Article
|
Aug 16, 2015 (publication date) through Nov 21, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Cases
ISSN
2307-8960
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: |
Crassini K, Mulligan SP, Best OG. Targeting chronic lymphocytic leukemia cells in the tumor microenviroment: A review of the |
|---|---|
| URL: | https://www.wjgnet.com/2307-8960/full/v3/i8/694.htm |
| Number | Citing Articles |
| 1 |
Quincy Quick. Microtubule-Actin Crosslinking Factor 1 and Plakins as Therapeutic Drug Targets. International Journal of Molecular Sciences 2018; 19(2): 368 doi: 10.3390/ijms19020368
|
| 2 |
Kyle Crassini, Yandong Shen, William S. Stevenson, Richard Christopherson, Chris Ward, Stephen P. Mulligan, O. Giles Best. MEK1/2 inhibition by binimetinib is effective as a single agent and potentiates the actions of Venetoclax and ABT‐737 under conditions that mimic the chronic lymphocytic leukaemia (CLL) tumour microenvironment. British Journal of Haematology 2018; 182(3): 360 doi: 10.1111/bjh.15282
|
| 3 |
Zengsheng Wang, Yan Li, Xiaochuan Kuang, Fang Guo, Tao Lang, Min Mao, Xiaoyan Zhang, Haiqing Yang. Anti-proliferation and pro-apoptosis effects of miR-582-5p in chronic lymphocytic leukemia via targeting HNRNPA1 and suppression of NF-κB. Molecular & Cellular Toxicology 2021; 17(3): 357 doi: 10.1007/s13273-021-00143-8
|
| 4 |
Sina Oppermann, Jarkko Ylanko, Yonghong Shi, Santosh Hariharan, Christopher C. Oakes, Patrick M. Brauer, Juan C. Zúñiga-Pflücker, Brian Leber, David E. Spaner, David W. Andrews. High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells. Blood 2016; 128(7): 934 doi: 10.1182/blood-2015-12-687814
|
| 5 |
Jerzy Kawiak, Grazyna Hoser, Joanna Domagała-Kulawik. Problems of Cancer Treatment. Part I. Theory of Treatment Based on Known Mechanisms of Anticancer Immunological Responses. Advances in Cell Biology 2017; 5(1): 72 doi: 10.1515/acb-2017-0006
|
| 6 |
Sarah Consalvo, Florian Hinterwimmer, Norbert Harrasser, Ulrich Lenze, Georg Matziolis, Rüdiger von Eisenhart-Rothe, Carolin Knebel. C-Reactive Protein Pretreatment-Level Evaluation for Ewing’s Sarcoma Prognosis Assessment—A 15-Year Retrospective Single-Centre Study. Cancers 2022; 14(23): 5898 doi: 10.3390/cancers14235898
|
| 7 |
Pavlina Janovska, Jan Verner, Jiri Kohoutek, Lenka Bryjova, Michaela Gregorova, Marta Dzimkova, Hana Skabrahova, Tomasz Radaszkiewicz, Petra Ovesna, Olga Vondalova Blanarova, Tereza Nemcova, Zuzana Hoferova, Katerina Vasickova, Lucie Smyckova, Alexander Egle, Sarka Pavlova, Lucie Poppova, Karla Plevova, Sarka Pospisilova, Vitezslav Bryja. Casein kinase 1 is a therapeutic target in chronic lymphocytic leukemia. Blood 2018; 131(11): 1206 doi: 10.1182/blood-2017-05-786947
|